Literature DB >> 11779298

Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.

K S Brown1, D J Levitt, M Shannon, B K Link.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11779298     DOI： 10.3816/clm.2001.n.026

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN： 1526-9655


× No keyword cloud information.
  11 in total

1.  MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death.

Authors:  Lei Jin; John C Stolpa; Ryan M Young; Aimee E Pugh-Bernard; Yosef Refaeli; John C Cambier
Journal:  Immunol Lett       Date:  2007-12-26       Impact factor: 3.685

2.  MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals.

Authors:  Lei Jin; Paul M Waterman; Karen R Jonscher; Cindy M Short; Nichole A Reisdorph; John C Cambier
Journal:  Mol Cell Biol       Date:  2008-06-16       Impact factor: 4.272

3.  SCIMP, a transmembrane adaptor protein involved in major histocompatibility complex class II signaling.

Authors:  Peter Draber; Ivana Vonkova; Ondrej Stepanek; Matous Hrdinka; Marketa Kucova; Tereza Skopcova; Pavel Otahal; Pavla Angelisova; Vaclav Horejsi; Mandy Yeung; Arthur Weiss; Tomas Brdicka
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

4.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

5.  Characterization of antibody-containing vesicles shed from B-lymphoma cell lines: exposure of annexin V binding sites.

Authors:  Rosana B Michel; Mones Abu-Asab; Maria Tsokos; M Jules Mattes
Journal:  Leuk Lymphoma       Date:  2006-11

Review 6.  Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

Authors:  Sanford Kempin
Journal:  Curr Treat Options Oncol       Date:  2013-06

7.  A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Authors:  Thomas S Lin; Wendy Stock; Huiping Xu; Mitch A Phelps; Margaret S Lucas; Sara K Guster; Bruce R Briggs; Carolyn Cheney; Pierluigi Porcu; Ian W Flinn; Michael R Grever; James T Dalton; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-12

Review 8.  Monoclonal antibody mechanisms of action in cancer.

Authors:  George J Weiner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 9.  B cell MHC class II signaling: A story of life and death.

Authors:  Divya Sai Katikaneni; Lei Jin
Journal:  Hum Immunol       Date:  2018-04-30       Impact factor: 2.850

10.  Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.

Authors:  Séverine Loisel; Pierre-Alain André; Josee Golay; Franz Buchegger; Jean Kadouche; Martine Cérutti; Luca Bologna; Marek Kosinski; David Viertl; Angelika Bischof Delaloye; Christian Berthou; Jean-Pierre Mach; Laurence Boumsell
Journal:  Mol Cancer       Date:  2011-04-19       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.